Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology_Personalized, Precision, Preemptive Medicines

Aviir, Inc.

Attachments

*Architects: Biotechnology_Personalized, Precision, Preemptive Medicines
*Industry: Southern California
*Portfolio Companies: Merck Global Health Innovation Fund
Architects: Cardiovascular, Cardiac & Cardiology Companies _ Pharmaceutical & Biotechnology

Aviir gets $4.2mm through late-stage financing (2010)
Aviir Inc Announces Agreement to Raise Up to $30 Million in Latest Financing Round (2011)
Aviir Inc Inks $10 Million (2013)
Aviir raises $12.95mm of a planned $25mm Series B round (2008)
Aviir’s TruRisk™ technology consists of a simple blood test that can be ordered by doctors for their patients so they can understand their risk of experiencing a heart attack and be motivated to do something about it.
Biotechnology company specializing in cardiac disease assessment
Commercial-stage diagnostic company focused on pharmacogenomic and genetic tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders
Founded 2005
Irvine, California
It then uses a complex algorithm to analyze those results and known risk factors to determine an individual’s probability of experiencing a heart attack within the next five years.
Merck Global Health Innovation Fund led the round. Current investors Bay City Capital, Aberdare Ventures, and New Leaf Venture Partners also participated.
Series E $10M by OnBioVC (2012)
The TruRisk™ technology measures the blood levels of 7 proteins associated with the development of unstable plaque.
TruRisk™, Aviir’s proprietary cardiac risk assessment technology, and additional molecular testing services provided through Aviir Heart Laboratories